Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

37.02 +0.18 (+0.49%)

Streaming Delayed Price Updated: 9:48 AM EDT, Aug 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare ↗

May 07, 2024

Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy.

Via InvestorPlace

3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 ↗

May 01, 2024

Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology.

Via InvestorPlace

Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know ↗

April 22, 2024

Via Benzinga

Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study ↗

April 02, 2024

Roivant Sciences and Priovant Therapeutics report Phase 2 results for brepocitinib in treating non-anterior non-infectious uveitis. Week 24 data show promising efficacy, with lower treatment failure...

Via Benzinga

Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study ↗

April 02, 2024

The company hopes to treat noninfectious uveitis and is rivaling AbbVie's Humira.

Via Investor's Business Daily

Where Roivant Sciences Stands With Analysts ↗

March 25, 2024

Via Benzinga

The Analyst Landscape: 4 Takes On Roivant Sciences ↗

February 14, 2024

Via Benzinga

Roivant Sciences Earnings Preview ↗

February 12, 2024

Via Benzinga

Assessing Roivant Sciences: Insights From 5 Financial Analysts ↗

January 02, 2024

Via Benzinga

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

April 02, 2024

From Roivant Sciences

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

March 29, 2024

Via Benzinga

Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase ↗

March 27, 2024

Solar stocks are racking up a strong day in trading, with several of the renewable energy firms up by double-digits in Wednesday trading.

Via Investor's Business Daily

Analyst Ratings for Roivant Sciences ↗

December 12, 2023

Via Benzinga

8 Analysts Have This to Say About Roivant Sciences ↗

November 14, 2023

Via Benzinga

Roivant Sciences Earnings Preview ↗

November 10, 2023

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

February 19, 2024

Via Benzinga

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update

February 13, 2024

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024

January 30, 2024

From Roivant Sciences

Via GlobeNewswire

Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space ↗

January 12, 2024

The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.

Via Investor's Business Daily

Earnings Scheduled For February 13, 2024 ↗

February 13, 2024

Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.

Via Benzinga

Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations ↗

January 10, 2024

Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to

Via Benzinga

Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50% ↗

December 21, 2023

Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in

Via Benzinga

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

December 20, 2023

From Roivant Sciences

Via GlobeNewswire

FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

December 20, 2023

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday.

Via Benzinga

Topics Stocks

Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease

December 14, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

November 28, 2023

From Roivant Sciences

Via GlobeNewswire

Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today? ↗

November 27, 2023

Roivant Sciences Ltd (NASDAQ: ROIV) and Priovant's Phase 2 study of oral brepocitinib in moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus (SLE)

Via Benzinga

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

November 27, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update

November 13, 2023

From Roivant Sciences

Via GlobeNewswire

Earnings Scheduled For November 13, 2023 ↗

November 13, 2023

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

All News about Roivant Sciences Ltd. - Common Shares

Starting at /week.